The national drug controller, Drug Controller General of India (DCGI), has approved a new oral therapy drug for multiple sclerosis, developed by Biogen Idec Biotech India.
The company has received approval for the first oral therapy drug for multiple sclerosis, Tecfidera by the DCGI.
Multiple Sclerosis
Multiple sclerosis can be a severely disabling autoimmune disease that affects the myelin or insulating layer of the nerve fibers and typically has remissions and relapses
Advertisement
Biogen Idec India Acting Managing Director Pooja Vatsyayan said, "We believe Tecfidera provides a new option for patients in India, particularly as it provides the convenience of oral dosing."
The clinical trials conducted for the approval of the drug involved two-phase III studies more than 2600 patients all around the world. Patients from India also were part of clinical research, Biogen Idec India said.
![Multiple Sclerosis Treatment and Modify]( "Multiple Sclerosis Treatment and Modify")
Multiple sclerosis is treated with drugs that modify the course of the disease, suppress immunity and relieve symptoms.
Tecfidera is the first oral drug for the treatment of relapsing-remitting multiple sclerosis (RRMS) in India, it added.
Multiple sclerosis is a disease, which affects brain and spinal cord and is the most common cause of non-traumatic neurological disability afflicting young adults, Biogen Idec India said.
Source: Medindia
Multiple Sclerosis Treatment and Modify
Multiple sclerosis is treated with drugs that modify the course of the disease, suppress immunity and relieve symptoms.
Advertisement
Tecfidera is the first oral drug for the treatment of relapsing-remitting multiple sclerosis (RRMS) in India, it added.
Multiple sclerosis is a disease, which affects brain and spinal cord and is the most common cause of non-traumatic neurological disability afflicting young adults, Biogen Idec India said.
Source: Medindia
Vitamin B12 - An Essential Vitamin
If you feel that the persistent or regular incidences of depression have got nothing to do with what you eat, think again. The reason behind low spirits can be due to insufficient levels vitamin B12.
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.
Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.
Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.
Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.
In case of cardiac failure where the ejection fraction is greater than 40%, sacubitril/valsartan can prove to be quite beneficial